Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes

Abstract excerpt

Prostate-specific membrane antigen (PSMA)–targeting α-radiation therapy (TAT) is an emerging treatment modality for metastatic castration-resistant prostate cancer. There is a subgroup of patients with poor response despite sufficient expression of PSMA in their tumors. The aim of this work was to characterize PSMA-TAT–nonresponding lesions by targeted next-generation sequencing. Methods: Of 60 patients treated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to PARP inhibition in cancer therapy
• Share to Prostate Cancer Treatment and Research
• Share to Radiopharmaceutical Chemistry and Applications